Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The Kawasaki Institute Of Industrial Promotion maintains a portfolio in the Biotechnology & Pharmaceuticals technology area with 3 pending office actions. These actions are distributed across 3 distinct examiners. This distribution shows that each pending matter is being evaluated by a different individual rather than being clustered under a single examiner.
SKOKO III, JOHN JOSEPH is identified as the busiest examiner, currently managing 1 pending office action. Since there are 3 distinct art units, the workload is spread across multiple specialized groups. This suggests that no single art unit has a disproportionate influence over the portfolio's current progress.
The presence of 3 distinct art units for the 3 pending office actions indicates a diverse range of technical subject matter within the Biotechnology & Pharmaceuticals sector. For the practitioner, this means that prosecution strategies must be tailored to the specific requirements of different units. SKOKO III, JOHN JOSEPH represents 1 of these unique points of contact.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SKOKO III, JOHN JOSEPH | 1 | 53.0% | +55.2% |
| GRABER, JAMES J | 1 | 46.5% | +57.6% |
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560006 | ANTIBODY HAVING REDUCED BINDING AFFINITY FOR ANTIGEN | SKOKO III, JOHN JOSEPH | — |
| 17745314 | MRNA FUNCTIONALIZATION METHOD | GRABER, JAMES J | — |
| 17613912 | COMPLEX, MEDICINE, THERAPEUTIC AGENT FOR CANCER, KIT AND CONJUGATE | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18560006 | ANTIBODY HAVING REDUCED BINDING AFFINITY FOR ANTIGEN | SKOKO III, JOHN JOSEPH | — |
| 17745314 | MRNA FUNCTIONALIZATION METHOD | GRABER, JAMES J | — |
| 17613912 | COMPLEX, MEDICINE, THERAPEUTIC AGENT FOR CANCER, KIT AND CONJUGATE | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1631 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18560006 | ANTIBODY HAVING REDUCED BINDING AFFINITY FOR ANTIGEN | SKOKO III, JOHN JOSEPH | 1643 | §102§103§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 17745314 | MRNA FUNCTIONALIZATION METHOD | GRABER, JAMES J | 1631 | §102§103§112Other | Non-Final OA | — | Pending | May 16, 2022 |
| 17613912 | COMPLEX, MEDICINE, THERAPEUTIC AGENT FOR CANCER, KIT AND CONJUGATE | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | — | Pending | Nov 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKawasaki Institute Of Industrial Promotion has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
John Joseph Skoko III has the most, with 1 of Kawasaki Institute Of Industrial Promotion's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
